Amarin (AMRN) Vascepa Exclusivity Status Not in FDA Orange Book March Update

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 10/5/2026

1. USO
2. NVDA
3. EVTL
4. PCVX
5. CME

6. MSFT
7. GMAB
8. ATH
9. LAES
10. SPY

April 12, 2013 10:35 AM EDT

Price: $12.35 --0%

Overall Analyst Rating:
SELL (= Flat)

Amarin Corp Plc (Nasdaq: AMRN) Vascepa exclusivity status isn't in FDA Orange Book update for March.

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!